Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (18,101,821)	$ (10,285,792)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Depreciation	6,661,010	6,398,481
Amortization of debt issuance costs	321,550	544,111
Stock based compensation expense related to issuance of restricted stock	21,746	21,954
Equity in loss of unconsolidated real estate ventures	1,561,373	607,602
Unrealized derivative gain	913,169	218,241
Derivative fair value adjustment		410,657
Unrealized foreign currency adjustment	3,873,704	(3,108,763)
Changes in operating assets and liabilities:
Other assets, net	(550,276)	354,725
Settlement of interest rate derivative		(2,030,731)
Purchase of interest rate derivative	(1,122,401)
Accounts payable and accrued liabilities	730,106	629,036
Due to affiliates	8,307,299	4,864,206
Net cash provided by (used in) operating activities	2,615,459	(1,376,273)
Cash flows from investing activities:
Additions to real estate facilities	(4,524,091)	(5,487,439)
Investment in company owned life insurance		(887,387)
Investments in unconsolidated real estate ventures	(718,579)	(2,562,445)
Return of capital on investments in unconsolidated real estate ventures	6,367,664
Net cash provided by (used in) investing activities	1,124,994	(8,937,271)
Cash flows from financing activities:
Proceeds from issuance of secured debt	5,588,659	173,028,608
Repayment of secured debt		(164,753,059)
Scheduled principal payments of secured debt	(1,299,331)	(881,005)
Debt issuance costs		(1,805,431)
Gross proceeds from issuance of common stock		15,170,192
Offering costs	(326,444)	(1,809,770)
Proceeds from issuance of Series C units		573,002
Redemption of common stock	(288,867)	(674,336)
Series E Preferred stock issuance costs	(110,692)
Distributions paid to common stockholders	(4,469,814)	(4,194,779)
Distributions paid to noncontrolling interest in our Operating Partnership	(170,045)	(169,886)
Distributions paid to preferred stockholders	(6,250,714)	(6,236,717)
Net cash provided by (used in) financing activities	(6,350,248)	8,246,819
Impact of foreign exchange rate changes on cash and restricted cash	(71,565)	671,828
Net change in cash, cash equivalents and restricted cash	(2,681,360)	(1,394,897)
Cash, cash equivalents and restricted cash, beginning of period	9,918,161	17,565,564
Cash, cash equivalents and restricted cash, end of period	7,236,801	16,170,667
Supplemental disclosures and non-cash transactions:
Cash paid for interest, net of amounts capitalized	8,756,932	6,821,587
Offering costs included in accounts payable and accrued liabilities		(882,357)
Other assets in due to affiliates	725,753
Interest rate swap contract in other assets	161,535	1,234,991
Interest rate swap contracts in accounts payable and accrued liabilities	171,871	371,144
Foreign currency hedge contract in other assets		1,190,074
Foreign currency translation adjustment	(1,453,069)	2,475,802
Issuance of shares pursuant to distribution reinvestment plan	3,337,776	3,271,464
Distributions payable to common and preferred stockholders	5,487,597	4,405,393
Distributions payable to noncontrolling interests in our Operating Partnership	28,029	28,029
Real estate and construction in process in accounts payable and accrued liabilities	885,307	1,834,367
Series E Preferred stock issuance costs in due to affiliates	348,381
Redemption of common stock in accounts payable and accrued liabilities	75,000	$ 3,106,935
Series E Preferred Stock
Cash flows from financing activities:
Gross proceeds from issuance of Series E preferred stock	$ 977,000